Original articleInformation and treatment decisions in severe spinal muscular atrophy: A parental follow-up
Introduction
Spinal muscular atrophy (SMA) is the second most common autosomal recessive disease, with an incidence of 1 in every 6000–10,000 live births.1 SMA affects motor neurons and exhibits various progression of muscle weakness. Based on age at presentation and severity, SMA is classified into four grades of severity. SMA type I is the most severe form and by definition presents during the first 6 months of life. Death usually occurs within the first 2 years of life without respiratory support, making SMA the second most common lethal autosomal recessive disease. SMA type II presents slightly later than type I, at 6–18 months, and is associated with a risk for shortened life expectancy. SMA type III causes symptoms after 18 months of age, and the life expectancy is generally in line with that of the general population. SMA type IV, finally, presents in the second or third decade of life, and walking ability is retained during adult years.1, 2
Despite promising novel therapeutic drugs in the pipeline for SMA, including the most severe forms, there is presently no cure for any form of SMA. Supportive and palliative care are therefore cornerstones in the treatment of severe SMA, focusing on preventing complications of weakness and maintaining quality of life. Key issues here involve respiratory and nutritional support.3 Life can be considerably prolonged for children with severe SMA by introducing respiratory support. However, the impact of such support on the child's wellbeing is unknown, and there is no evidence or consensus among experts on the use of respiratory support for SMA type I. In the absence of consensus, Wang and co-workers4 developed care guidelines for SMA based on evidence and a Delphi consensus-building process. Their guidelines concluded that caregivers should explore treatment options together with the family in relation to the child's potential, quality-of-life issues, and family desires. This need is particularly evident and important regarding the use of respiratory support.4 A key issue is to what extent respiratory support affects the quality of life of the child with severe SMA, and recommendations vary between clinics and clinicians. Some favor the use of respiratory support for SMA type I,5, 6, 7 while others strongly oppose its use,8, 9 arguing that the burden for the child and family is greater than the benefit. The international care guidelines from 2007 consider such differences in treatment recommendations, and conclude that clinicians have an obligation to present treatment options to the parents in an open, fair and balanced manner.4
Although there is evidence from other severe childhood diseases that parent information and participation in decision making has a high impact on the end-of-life care and parents' and children's wellbeing,10, 11, 12 little is known about the situation for parents of children with severe SMA. The few existing studies on SMA13, 14, 15 have examined parents' experience of having a child with SMA but from a different perspective. Higgs and co-workers15 interviewed 13 bereaved parents from seven families about their experiences of having a child with SMA type I. These parents described the shock, the anticipatory grief, the helplessness, but also that they were grateful for being given control over decisions, e.g. about how and where their child died. In the interview study by Parker, Maddocks and Stern,14 nine bereaved and four non-bereaved family members of individuals with muscular dystrophy or SMA perceived a lack of coordination of care and competent health care professionals, inadequate bereavement care, and limited discussions of options for respiratory support and advance directives.
When a child is diagnosed with severe SMA, parents and caregivers are confronted with many difficult treatment decisions and emotionally demanding situations. In order to arrange care in accordance with the families' wishes and concerns, we need more knowledge about the parents' perspective on the child's care. Therefore, we have carried out a nationwide study to explore the experience of non-bereaved and bereaved parents of children with severe SMA, where respiratory support was considered during the first year of the child's life, concerning information and treatment decisions.
Section snippets
Material and methods
This study is based on a nationwide survey, conducted in 2013, of the parents of children who were born in Sweden between the years 2000 and 2010 and later diagnosed with SMA type I or II, and for whom respiratory support was considered by the health care professionals during the first year of life. The children (N = 40) were identified through the National Board of Health and Welfare and their parents/guardians through the Swedish Tax Agency (N = 78) (Fig. 1). Altogether, 70 parents of 37
Demographic and clinical characteristics
The participating parents consisted of an almost equal number of mothers and fathers (Table 1). The parents' mean age was close to 40 years at time of follow-up. The children still alive at follow-up had a mean age of 9.7 years. The deceased children's mean age at the time of death was 9.5 months. The most common type of respiratory support reported by the parents of the children who were alive at follow-up was non-invasive ventilation by mask (N = 11). The deceased children had most commonly
Discussion
None of the participating parents reported that health care professionals had made decisions concerning the child's medical treatment without informing them first and 80% of the parents reported feeling confident about decisions made concerning their child's treatment. When respiratory support was discussed, ventilation by mask was the option parents were most commonly informed about, but a quarter reported that they got no information about respiratory support at all. A vast majority of those
Acknowledgements
We would like to thank the participating parents who bravely shared their experiences with us, Elin Hjorth who has worked with the database, and Christina Renlund for her valuable work with the families and the surveys.
References (25)
- et al.
Spinal muscular atrophy: a clinical and research update
Pediatr Neurol
(2012) - et al.
Childhood spinal muscular atrophy: controversies and challenges
Lancet Neurol
(2012) - et al.
Parents' intellectual and emotional awareness of their child's impending death to cancer: a population-based long-term follow-up study
Lancet Oncol
(2007) - et al.
Parents' experiences of pediatric palliative care and the impact on long-term parental grief
J Pain Symptom Manag
(2014) - et al.
Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe
J Neurol
(2014) Modern management of spinal muscular atrophy
J Child Neurol
(2007)- et al.
Consensus statement for standard of care in spinal muscular atrophy
J Child Neurol
(2007) - et al.
Spinal muscular atrophy type 1: management and outcomes
Pediatr Pulmonol
(2002) - et al.
Long-term ventilator support in patients with Werdnig-Hoffmann disease
Pediatr Int
(2000) - et al.
Tracheotomy and children with spinal muscular atrophy type 1: ethical considerations in the French context
Nurs Ethics
(2012)